comparemela.com

Latest Breaking News On - Ulrich laufs - Page 1 : comparemela.com

Earlier Evolocumab Cut CVD, CV Mortality Over Longer Term: FOURIER-OLE

In the extension study, when placebo patients were switched to PCSK9 inhibitor treatment, they made gains, but didn’t catch up.

United statesComunidad autonoma de catalunaSanofi regeneronUlrich laufsMichelle odonoghueMichael shapiroEuropean society of cardiologyPhd leipzig universityDo wake forest university school of medicineMichelleo donoghueEuropean societyWake forest university schoolLeipzig university

Evolocumab Benefits Accrue With Longer Follow-up: FOURIER OLE

Chief among them was a reduction in cardiovascular mortality not observed in the pivotal trial that led to US approval of the drug.

United statesJohann bauersachsUlrich laufsMichelle odonoghueEuropean society of cardiologyHannover medical schoolSaarland or leipzig universityLeipzig university hospitalMichelleo donoghueEuropean societyLeipzig universityErebrovascular accidentVa cerebrovascular accidentIpid managementMyocardial infarctionCardiovascular disease

Elevated Risks From Lp(a) Can Be Offset by Lower Lifetime LDL Cholesterol

To get this benefit, people with high Lp(a) need to maintain LDL-cholesterol levels 20 mg/dL lower than if they had normal Lp(a).

Ulrich laufsMd university of cambridgeNovartis pharmaceuticalsEuropean atherosclerosis societyMd leipzig universityUnited kingdomMeans lowerUnited kingdom biobankLeipzig universitySilence therapeutics

vimarsana © 2020. All Rights Reserved.